Resmed (RMD) Stock Price

Resmed Price

NYSE·CLOSED
219.47USD+7.53 (+3.49 %)
Market closed

Revenue has compounded at 11.5% per year over the past 19 years to 5.65 B USD. Earnings per share have grown at 18.4% per year over the last 19 years. Resmed's net margin stands at 26.9%, up from 21.8% several years earlier. Resmed currently offers a dividend yield of about 1.09%. The payout ratio is around 28% of earnings. The dividend has grown at 15.0% per year over the past 14 years. Analysts set a median price target of 306.00 USD, implying 39.4% above the current price. Of 25 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.

Resmed stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Resmed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Resmed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Resmed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Resmed Stock Price History
DateResmed Price
8/10/2026219.47 USD
8/7/2026211.94 USD
8/6/2026223.24 USD
8/5/2026222.57 USD
8/4/2026220.37 USD
8/3/2026215.19 USD
7/31/2026210.98 USD
7/30/2026208.56 USD
7/29/2026213.16 USD
7/27/2026202.79 USD
7/23/2026191.89 USD
7/22/2026192.91 USD
7/21/2026195.80 USD
7/20/2026198.61 USD
7/17/2026198.99 USD
7/16/2026202.76 USD
7/15/2026198.57 USD
7/14/2026193.01 USD
7/13/2026198.49 USD
7/10/2026203.87 USD
7/9/2026208.45 USD
7/8/2026210.95 USD
7/7/2026219.75 USD
7/6/2026215.99 USD
7/2/2026209.63 USD
7/1/2026201.10 USD
6/30/2026194.88 USD
6/29/2026199.77 USD
6/26/2026200.29 USD
6/25/2026198.60 USD
6/24/2026196.50 USD
6/23/2026191.26 USD
6/22/2026189.46 USD
6/18/2026189.04 USD
6/17/2026189.22 USD
6/16/2026194.93 USD
6/15/2026195.13 USD
6/12/2026194.83 USD
6/11/2026192.66 USD
6/10/2026196.29 USD
6/9/2026196.94 USD
6/8/2026193.14 USD
6/5/2026197.66 USD
6/4/2026192.04 USD
6/3/2026186.37 USD
6/2/2026184.18 USD
6/1/2026186.99 USD
5/29/2026199.23 USD
5/28/2026206.27 USD
5/27/2026210.40 USD
5/26/2026209.41 USD
5/22/2026207.70 USD
5/21/2026208.40 USD
5/20/2026210.12 USD
5/19/2026207.78 USD
5/18/2026204.15 USD
5/15/2026201.88 USD
5/14/2026202.46 USD
5/13/2026202.37 USD
5/12/2026203.79 USD
5/11/2026198.76 USD
5/8/2026206.76 USD
5/7/2026206.89 USD
5/6/2026209.64 USD
5/5/2026207.88 USD
5/4/2026209.43 USD
5/1/2026205.02 USD
4/30/2026213.81 USD
4/29/2026211.93 USD
4/28/2026217.14 USD
4/27/2026222.02 USD
4/24/2026219.85 USD
4/22/2026222.04 USD
4/21/2026221.22 USD
4/20/2026226.14 USD
4/17/2026228.12 USD
4/16/2026224.72 USD
4/15/2026228.80 USD
4/14/2026230.69 USD
4/13/2026230.26 USD
4/10/2026228.87 USD
4/9/2026227.98 USD
4/8/2026230.70 USD
4/7/2026226.05 USD
4/6/2026224.93 USD
4/2/2026221.45 USD
4/1/2026222.85 USD
3/31/2026224.48 USD
3/30/2026220.03 USD
3/27/2026220.47 USD
3/26/2026222.46 USD
3/25/2026226.31 USD
3/24/2026228.19 USD
3/23/2026228.01 USD
3/20/2026228.12 USD
3/19/2026227.41 USD
3/18/2026227.41 USD
3/17/2026233.50 USD
3/16/2026230.11 USD
3/13/2026230.84 USD
3/12/2026232.41 USD
3/11/2026240.15 USD
3/10/2026247.11 USD
3/9/2026252.93 USD
3/6/2026252.87 USD
3/5/2026255.32 USD
3/4/2026259.05 USD
3/3/2026258.28 USD
3/2/2026257.39 USD
2/27/2026256.26 USD
2/26/2026257.06 USD
2/25/2026252.53 USD
2/24/2026251.63 USD
2/23/2026260.79 USD
2/20/2026259.12 USD
2/19/2026256.29 USD
2/18/2026258.91 USD
2/17/2026255.82 USD
2/13/2026252.55 USD
2/12/2026245.73 USD
2/11/2026259.62 USD
2/10/2026263.54 USD
2/9/2026275.96 USD
2/6/2026271.63 USD
2/5/2026267.05 USD
2/4/2026263.03 USD
2/3/2026251.41 USD
2/2/2026254.74 USD
1/30/2026258.31 USD
1/29/2026257.61 USD
1/28/2026257.72 USD
1/27/2026255.51 USD
1/26/2026255.47 USD
1/23/2026252.38 USD
1/22/2026255.36 USD
1/21/2026259.28 USD
1/20/2026253.20 USD
1/16/2026257.58 USD
1/15/2026260.70 USD
1/14/2026259.51 USD
1/13/2026254.67 USD
1/12/2026257.84 USD
1/9/2026252.01 USD
1/8/2026250.92 USD
1/7/2026248.21 USD
1/6/2026249.19 USD
1/5/2026245.36 USD
1/2/2026244.81 USD
12/31/2025240.91 USD
12/30/2025243.08 USD
12/29/2025242.85 USD
12/26/2025244.76 USD
12/24/2025244.44 USD
12/23/2025244.60 USD
12/22/2025246.67 USD
12/19/2025244.94 USD
12/18/2025242.55 USD
12/17/2025245.94 USD
12/16/2025247.34 USD
12/15/2025253.07 USD
12/12/2025252.27 USD
12/11/2025252.39 USD
12/10/2025251.50 USD
12/9/2025246.52 USD
12/8/2025250.04 USD
12/5/2025256.55 USD
12/4/2025251.51 USD
12/3/2025251.44 USD
12/2/2025250.85 USD
12/1/2025248.38 USD
11/28/2025255.83 USD
11/26/2025255.92 USD
11/25/2025255.80 USD
11/24/2025250.52 USD
11/21/2025250.75 USD
11/20/2025243.92 USD
11/19/2025244.99 USD
11/18/2025246.22 USD
11/17/2025244.71 USD
11/14/2025244.46 USD
11/13/2025252.11 USD
11/12/2025252.86 USD
11/11/2025252.43 USD
11/10/2025250.10 USD
11/7/2025251.49 USD
11/6/2025249.65 USD
11/5/2025245.22 USD
11/4/2025246.40 USD
11/3/2025248.95 USD
10/31/2025246.88 USD
10/30/2025255.01 USD
10/29/2025253.62 USD
10/28/2025256.57 USD
10/27/2025259.21 USD
10/24/2025259.49 USD
10/23/2025265.26 USD
10/22/2025266.48 USD
10/21/2025268.22 USD
10/20/2025271.41 USD
10/17/2025268.10 USD
10/16/2025270.00 USD
10/15/2025269.70 USD
10/14/2025270.07 USD
10/13/2025273.01 USD
10/10/2025272.91 USD
10/9/2025277.88 USD
10/8/2025282.35 USD
10/7/2025283.28 USD
10/6/2025281.38 USD
10/3/2025279.01 USD
10/2/2025276.64 USD
10/1/2025270.85 USD
9/30/2025273.73 USD
9/29/2025271.05 USD
9/28/2025271.05 USD
9/25/2025270.27 USD
9/24/2025267.31 USD
9/23/2025275.61 USD
9/22/2025274.41 USD
9/19/2025273.20 USD
9/18/2025273.29 USD
9/17/2025271.71 USD
9/16/2025272.60 USD
9/15/2025271.19 USD
9/12/2025270.15 USD
9/11/2025274.61 USD
9/10/2025270.47 USD
9/9/2025279.19 USD
9/8/2025279.46 USD
9/5/2025271.52 USD
9/4/2025272.67 USD
9/3/2025269.21 USD
9/2/2025270.99 USD
8/29/2025273.25 USD
8/28/2025275.38 USD
8/27/2025281.96 USD
8/26/2025285.17 USD
8/25/2025285.80 USD
8/22/2025293.27 USD
8/21/2025288.34 USD
8/20/2025289.06 USD
8/19/2025286.04 USD
8/18/2025286.12 USD
8/15/2025284.89 USD
8/14/2025284.72 USD
Access this data via the Eulerpool API
Get Free API Key

Resmed Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
4.22 B USD
1.13 B USD
897.56 M USD
Jan 1, 2024
4.69 B USD
1.32 B USD
1.02 B USD
Jan 1, 2025
5.15 B USD
1.69 B USD
1.40 B USD
Jan 1, 2026
5.65 B USD
1.89 B USD
1.52 B USD
Jan 1, 2027 (e)
5.81 B USD
2.18 B USD
1.78 B USD
Jan 1, 2028 (e)
6.19 B USD
2.33 B USD
1.95 B USD
Jan 1, 2029 (e)
6.81 B USD
2.50 B USD
2.08 B USD
Jan 1, 2030 (e)
7.70 B USD
2.83 B USD
2.38 B USD

Resmed Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 14, 2026, 12:31 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESM
2015201620172018201920202021202220232024202520262027e2028e2029e2030e
1.681.842.072.342.612.963.203.584.224.695.155.655.816.196.817.70
7.989.5412.4013.2611.3713.478.0811.9518.0010.979.849.852.816.4510.0213.12
60.2558.0058.1358.2158.9458.0757.5456.5755.7856.6759.3561.1561.1561.1561.1561.15
1.011.071.201.361.541.721.842.022.362.663.053.463.553.784.164.71
0.410.430.430.540.580.810.900.981.131.321.691.892.182.332.502.83
24.3723.2920.5723.1222.2227.3628.2527.4526.7928.1532.7433.4737.5437.5836.7036.70
0.350.350.340.320.400.620.470.780.901.021.401.521.781.952.082.38
2.03–-2.84-7.8928.2553.71-23.6764.3515.1513.7137.258.7917.019.486.4614.54
1.161.261.361.441.521.561.621.721.842.022.262.402.622.853.11–
9.438.627.945.885.562.633.856.176.989.7811.886.199.178.789.12–
141.15142.10143.86144.35145.58146.42147.04147.41147.55147.60147.04144.98144.98144.98144.98144.98
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Resmed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Resmed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Resmed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Resmed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Resmed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Resmed stock margins

The Resmed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Resmed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Resmed.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
56.57 %
27.47 %
21.78 %
Jan 1, 2023
55.78 %
26.80 %
21.25 %
Jan 1, 2024
56.67 %
28.17 %
21.79 %
Jan 1, 2025
59.36 %
32.75 %
27.22 %
Jan 1, 2026
61.16 %
33.48 %
26.94 %
Jan 1, 2027 (e)
61.16 %
37.55 %
30.66 %
Jan 1, 2028 (e)
61.16 %
37.59 %
31.53 %
Jan 1, 2029 (e)
61.16 %
36.71 %
30.52 %

Resmed Stock Revenue, EBIT, Earnings per Share

The Resmed earnings per share therefore indicates how much revenue Resmed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2022
24.27 USD
6.67 USD
5.29 USD
Jan 1, 2023
28.62 USD
7.67 USD
6.08 USD
Jan 1, 2024
31.74 USD
8.94 USD
6.92 USD
Jan 1, 2025
35.00 USD
11.46 USD
9.53 USD
Jan 1, 2026
39.00 USD
13.05 USD
10.51 USD
Jan 1, 2027 (e)
39.45 USD
15.05 USD
12.10 USD
Jan 1, 2028 (e)
41.99 USD
16.04 USD
13.24 USD
Jan 1, 2029 (e)
46.20 USD
17.24 USD
14.10 USD

Resmed business model & stock analysis

ResMed Inc. is a global leading provider of medical devices for the treatment of sleep disorders and respiratory diseases. The company was founded in Australia by Peter Farrell, a former employee of the University of New South Wales, in 1989. Today, ResMed is headquartered in San Diego, California, and employs over 7,500 people worldwide. Business model: ResMed's business model is based on providing medical products and solutions for the treatment of sleep apnea and other respiratory diseases. The company develops and distributes masks, devices, and accessories that help patients breathe better and achieve restful sleep. ResMed also offers cloud-based software solutions and services to assist doctors and sleep labs in diagnosing and monitoring patients. Products and divisions: ResMed's product range can be divided into four main divisions: Sleep & Respiratory Care, Software as a Service (SaaS), Technologies, and Dental Solutions. Sleep & Respiratory Care: In this division, ResMed offers a wide range of masks, devices, and accessories for the treatment of sleep apnea and other respiratory diseases. The most well-known products include the AirSense and AirMini devices, equipped with Automatic Sleep Detection and AutoSet algorithm to optimize respiratory pressure. ResMed also offers a range of CPAP masks, nasal and full face masks, as well as nasal pillow masks. Software as a Service (SaaS): ResMed's cloud-based software solutions and services are offered under the brand AirView. They include diagnostic tools, patient monitoring systems, and analysis tools. AirView allows doctors to access their patients' medical data captured by ResMed devices and monitor this data in real-time. Technologies: ResMed's Technologies division focuses on the development of advanced sensors for respiratory and sleep monitoring. Products include the S+, a smart sleep tracking system that operates without direct body contact, and the Reveal-LTE, an implant for monitoring heart and respiratory rates in patients with heart failure. Dental Solutions: ResMed has also developed products for dentistry to assist patients with mild to moderate upper airway obstruction. Products include the Narval CC, a custom-made dental device for the treatment of snoring and sleep apnea, and the Tap Pap nasal pillow oral appliance, a non-invasive mouthguard. Conclusion: ResMed is a leading provider of medical devices and solutions for the treatment of sleep apnea and other respiratory diseases. The company offers innovative products and technologies that help patients breathe better and achieve restful sleep. ResMed's cloud-based software solutions enable doctors to monitor their patients' health in real-time and develop effective diagnosis and treatment strategies. With its wide range of products, innovation, and highly qualified team of scientists, engineers, and medical professionals, ResMed will continue to play an important role in the healthcare industry.

Resmed SWOT Analysis

Strengths

Resmed Inc has several strengths that contribute to its success in the market. Firstly, the company has a strong brand reputation and is recognized as a leader in the sleep and respiratory care industry. This gives Resmed a competitive advantage over its rivals. Additionally, Resmed has a comprehensive range of products and solutions that cater to different customer needs, ensuring a diverse customer base. Moreover, the company invests heavily in research and development, allowing it to innovate and bring cutting-edge technologies to the market. This positions Resmed as an industry pioneer with a constant stream of new and improved products.

Weaknesses

Despite its strengths, Resmed Inc also faces some weaknesses. One of the major weaknesses is the heavy reliance on a limited number of suppliers for key components. Any disruption in the supply chain can significantly affect Resmed's production and distribution capabilities. Additionally, Resmed's high dependence on Medicare and reimbursement policies creates vulnerability to changes in healthcare regulations. This can impact the company's profitability and restrict market expansion.

Opportunities

Resmed Inc has numerous opportunities in the market that it can capitalize on. With the growing awareness of sleep apnea and other respiratory conditions, there is a significant demand for effective treatment devices and solutions. Resmed can expand its market share by targeting emerging markets where awareness and access to healthcare are increasing. Furthermore, the company can explore partnerships and collaborations with healthcare providers to enhance product distribution and reach a larger customer base. The continuous advancements in technology also present opportunities for Resmed to develop and introduce more advanced, user-friendly, and connected solutions.

Threats

Resmed Inc faces several threats that could impact its business operations. One of the main threats is intense competition from both established players and new entrants in the sleep and respiratory care industry. Price wars, rapid technological advancements, and changing consumer preferences make it crucial for Resmed to continuously innovate and differentiate its products. Another threat is the potential impact of economic downturns, as disposable income and healthcare spending may decrease. Finally, strict regulations and compliance requirements can pose challenges to Resmed's ability to expand into new markets and launch products in a timely manner.

Resmed Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Resmed Employees
Details
Date
Resmed Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Resmed Segments

Resmed Revenue by Segment (1/3)

  • 3 Years

  • Max

Sleep and Breathing Health
Sleep and Respiratory Care products
Residential Care Software
Software as a Service
Details
Date
Sleep and Breathing Health
Sleep and Respiratory Care products
Sleep And Respiratory
Devices
Flow Generators
Mask Systems, Motors And Other Accessories
Residential Care Software
Software as a Service
Jan 1, 2023
0.00 USD
3.73 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
497.98 M USD
Jan 1, 2025
4.50 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
641.44 M USD
0.00 USD

Resmed Revenue by Segment (2/3)

  • Max

Sleep and Breathing Health
Residential Care Software
Details
Date
Sleep and Breathing Health
Residential Care Software
Jan 1, 2023
0.00 USD
0.00 USD
Jan 1, 2025
4.50 B USD
641.44 M USD

Resmed Revenue by Segment (3/3)

  • 3 Years

  • Max

Sleep and Respiratory Care
Software as a Service
Details
Date
Sleep and Respiratory Care
Software as a Service
Jan 1, 2023
3.73 B USD
497.98 M USD
Jan 1, 2025
0.00 USD
0.00 USD

Resmed Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Global revenue
United States
Global
U.S., Canada and Latin America
International
Combined Europe, Asia and other markets
North and Latin America
Combined Europe Asia And Other Markets
D [E]
F [R]
A [U]
Details
Date
Global revenue
United States
Global
U.S., Canada and Latin America
International
Combined Europe, Asia and other markets
North and Latin America
Combined Europe Asia And Other Markets
D [E]
F [R]
A [U]
Jan 1, 2017
0.00 USD
1.23 B USD
0.00 USD
0.00 USD
684.26 M USD
0.00 USD
0.00 USD
0.00 USD
153.28 M USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
1.35 B USD
0.00 USD
0.00 USD
994.98 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
1.59 B USD
2.61 B USD
1.70 B USD
1.02 B USD
0.00 USD
0.00 USD
910.30 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
1.83 B USD
2.96 B USD
1.93 B USD
1.13 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
1.96 B USD
3.20 B USD
2.08 B USD
1.23 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
3.58 B USD
2.25 B USD
0.00 USD
2.38 B USD
1.33 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
4.22 B USD
2.72 B USD
0.00 USD
0.00 USD
1.50 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
3.29 B USD
0.00 USD
3.00 B USD
1.86 B USD
1.51 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Resmed Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Resmed historical P/E ratio, EBIT multiple, and P/S ratio

Resmed annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Resmed shares outstanding

The number of shares of Resmed was 147.04 M in 2025. This indicates how many shares Resmed is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2022
147.41 M Stocks
Jan 1, 2023
147.55 M Stocks
Jan 1, 2024
147.60 M Stocks
Jan 1, 2025
147.04 M Stocks
Jan 1, 2026
144.98 M Stocks
Jan 1, 2027 (e)
144.98 M Stocks
Jan 1, 2028 (e)
144.98 M Stocks
Jan 1, 2029 (e)
144.98 M Stocks

Resmed stock splits

In Resmed's history, there have been no stock splits.

Resmed Dividend History

15 years of dividend payments · 13 consecutive increases

YearAnnual DividendYoY ChangePayments
20261.20USDYTD—2×
Feb 12, 20260.60USD 0.0%1/2
May 14, 20260.60USD 0.0%2/2
20252.26USD↑ 11.9%4×
Feb 13, 20250.53USD 0.0%1/4
May 8, 20250.53USD 0.0%2/4
Aug 14, 20250.60USD↑ 13.2%3/4
Nov 13, 20250.60USD 0.0%4/4
20242.02USD↑ 9.8%4×
20231.84USD↑ 7.0%4×
20221.72USD↑ 6.2%4×
20211.62USD↑ 3.8%4×
20201.56USD↑ 2.6%4×
20191.52USD↑ 5.6%4×
20181.44USD↑ 5.9%4×
20171.36USD↑ 7.9%4×

Resmed dividend history and estimates

In 2025, Resmed paid a dividend amounting to 2.26 USD. Dividend means that Resmed distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2022
1.72 USD
0.00 USD
Jan 1, 2023
1.84 USD
0.00 USD
Jan 1, 2024
2.02 USD
0.00 USD
Jan 1, 2025
2.26 USD
0.00 USD
Jan 1, 2026
2.40 USD
0.00 USD
Jan 1, 2027 (e)
0.00 USD
2.62 USD
Jan 1, 2028 (e)
0.00 USD
2.85 USD
Jan 1, 2029 (e)
0.00 USD
3.11 USD

Resmed dividend payout ratio

In 2025, Resmed had a payout ratio of 23.72%. The payout ratio indicates the percentage of the company's profits that Resmed distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2022
32.53 %
Jan 1, 2023
30.25 %
Jan 1, 2024
29.20 %
Jan 1, 2025
23.72 %
Jan 1, 2026
27.72 %
Jan 1, 2027 (e)
21.63 %
Jan 1, 2028 (e)
21.53 %
Jan 1, 2029 (e)
22.04 %

Current Resmed forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.33 %
Buy
64.00 % (16)
Hold
32.00 % (8)
Sell
4.00 % (1)
12M Price Target
306.00
Last Price
226.00
Currency
USD
12M Return Potential
35.40 %
LTM Return
0 %

Resmed Analyst Rating Actions

DateFirmActionRatingReliability
7/15/2026
Mizuho
Mizuho
MaintainedOutperform31
7/13/2026
Citigroup
Citigroup
DowngradeBuyNeutral48
7/10/2026
Jefferies
Jefferies
MaintainedHold47
7/8/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
7/8/2026
RBC Capital
RBC Capital
MaintainedOutperform52
6/22/2026
Keybanc
Keybanc
MaintainedOverweight49
6/17/2026
Morgan Stanley
Morgan Stanley
DowngradeOverweightEqual Weight60
6/15/2026
Citigroup
Citigroup
MaintainedBuy48
5/1/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
5/1/2026
RBC Capital
RBC Capital
MaintainedOutperform52

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Resmed Earnings Calls

2025

Resmed Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/20262.92USD-1.47 BUSD-2026 Q4
4/30/20262.83USD-1.43 BUSD-2026 Q3
1/29/20262.75USD-1.41 BUSD-2026 Q2
4/25/20241.87USD-1.18 BUSD-2024 Q3
1/24/20241.79USD-1.16 BUSD-2024 Q2
8/9/20231.71USD-1.04 BUSD-2023 Q4
4/26/20231.62USD-1.01 BUSD-2023 Q3
1/25/20231.61USD-1.00 BUSD-2023 Q2
10/27/20221.53USD-958.24 MUSD-2023 Q1
8/11/20221.47USD-926.66 MUSD-2022 Q4
...

EESG©

Eulerpool ESG Scorecard© for the Resmed stock

86/100
99
Environment
99
Social
59
Governance
E

Environment

20
Scope 1 - Direct Emissions4,236
Scope 2 - Indirect emissions from purchased energy24,422
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions28,658
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees53.69
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Resmed shareholder structure

% Name
8.20824%
BLACKROCK, INC.
BLACKROCK, INC.
6.42488%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
5.33726%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
4.50873%
STATE STREET CORP
STATE STREET CORP
3.34287%
BANK OF NEW YORK MELLON CORP
BANK OF NEW YORK MELLON CORP
2.95431%
GEODE CAPITAL MANAGEMENT, LLC
GEODE CAPITAL MANAGEMENT, LLC
...

Resmed Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
11.06%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
9.30%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
8.47%
Colonial First State Investment Group Limited
Colonial First State Investment Group Limited
SEC ↗
8.21%
Vanguard Capital Management
Vanguard Capital Management
SEC ↗
7.71%
Edward C. Johnson 3d
Edward C. Johnson 3d
SEC ↗
6.21%
WCM Investment Management, LLC
WCM Investment Management, LLC
SEC ↗
6.11%
36-2214610
36-2214610
SEC ↗
5.82%
FMR LLC
FMR LLC
SEC ↗
5.82%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
5.73%
Westpac Financial Services Group Limited
Westpac Financial Services Group Limited
SEC ↗

Resmed Executives and Management Board

15 members · avg. age 62 · 27 % women

MF

Mr. Michael Farrell (53)

Chairman of the Board, Chief Executive Officer · since 2005

14.67 M USD

Management

JL

Mr. Justin Leong (48)

Chief Product Officer

3.91 M USD
BS

Mr. Brett Sandercock (58)

Chief Financial Officer

3.57 M USD
MR

Mr. Michael Rider (68)

Global General Counsel, Company Secretary

2.29 M USD

Board of Directors

PF

Dr. Peter Farrell (83)

Founder and Chairman Emeritus · since 2023

673,267.00 USD
CD

Mr. Christopher Delorefice (54)

Independent Director

377,745.00 USD
RT

Mr. Ronald Taylor (77)

Lead Independent Director

369,909.00 USD
CB

Ms. Carol Burt (67)

Independent Director

366,719.00 USD
KD

Ms. Karen Drexler (65)

Independent Director

349,909.00 USD
RS

Mr. Richard Sulpizio (74)

Independent Director

344,909.00 USD

Resmed Supply Chain

Resmed Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
11 companies
#Nameβ 1YTrend
1
Hi-Clearance Inc.
Customer
-0.73
0.14
-0.69
0.19
0.54
0.81
—
2
CTS
Supplier
0.38
-0.36
-0.50
0.11
0.46
0.62
0.56
3
AdaptHealth A
Customer
0.64
0.75
-0.48
-0.57
-0.52
0.54
-1.03
4
AIMS APAC REIT
Supplier
0.67
0.13
-0.23
0.76
0.75
0.46
—
#Nameβ 1YTrend
1
Altium Limited
Supplier
0.62
-0.46
—
—
—
—
—
2
Apria
Customer
-0.30
0.34
0.94
0.56
—
—
—
3
Magic Software Enterprises Ltd.
Supplier
-0.59
0.01
0.90
0.81
—
—
—
4
Orion B
Supplier·Customer
0.45
0.71
-0.85
-0.47
-0.32
-0.44
-0.41
5
Altium
Supplier
-0.80
-0.51
-0.63
0.67
0.31
0
—

Frequently asked questions about Resmed

Resmed Inc operates with a business model focused on the development and manufacturing of medical equipment for the management of sleep-disordered breathing and chronic respiratory diseases. The company's core products include devices for the treatment of sleep apnea, ventilators, and respiratory care solutions. Resmed Inc's business model emphasizes innovation and research to provide superior quality products to improve the lives of individuals suffering from these conditions. With a strong commitment to advancing respiratory healthcare, Resmed Inc has established itself as a leading global provider of sleep and respiratory medical devices and solutions.

Resmed Inc is primarily active in the industries of medical devices and sleep apnea solutions.

Resmed Inc faces competition from prominent companies in the market. Some of its main competitors include Philips Respironics, Fisher & Paykel Healthcare, and ResMed Ltd. These companies also specialize in providing solutions for sleep and respiratory disorders. Resmed Inc competes on various fronts in the market, including product innovation, quality, and customer service. Despite the competitive landscape, Resmed Inc has established itself as a leading player in the industry, offering cutting-edge products to improve sleep apnea and respiratory care.

ResMed Inc. is a leading global company that specializes in the development and manufacturing of innovative medical devices and solutions for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in 1989, ResMed has evolved into a pioneer in sleep medicine, providing a wide range of products such as masks, devices, and software to improve respiratory health and enhance the quality of life for millions of patients worldwide. With a commitment to continuous innovation and cutting-edge technology, ResMed has established itself as a trusted and renowned name in the medical industry, dedicated to improving the well-being of individuals affected by respiratory disorders.

ResMed Inc has achieved significant milestones since its establishment. The company revolutionized the sleep apnea industry by introducing innovative and effective solutions for patients worldwide. ResMed pioneered the development of continuous positive airway pressure (CPAP) therapy, offering a breakthrough treatment method that significantly improved patient outcomes. Utilizing advanced technology and research, ResMed expanded its product line to include state-of-the-art sleep and respiratory care devices. The company's commitment to innovation and patient-centered solutions has led to numerous awards and recognitions, solidifying ResMed's position as a global leader in the sleep health industry. ResMed Inc continues to drive advancements in sleep apnea and respiratory care, improving the lives of millions.

Resmed Inc is primarily present in various countries and regions across the globe. The company has a strong presence in the United States, where its headquarters is located. It also operates and serves customers in Australia, Canada, France, Germany, Japan, and the United Kingdom. Additionally, Resmed Inc has expanded its reach to many other countries in Europe, Asia, and the Americas. With its global presence, Resmed Inc continues to provide innovative solutions and improve the well-being of individuals suffering from sleep apnea and other respiratory disorders.

Resmed Inc is a leading global medical technology company specializing in the development and manufacturing of innovative devices and solutions for sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company is dedicated to improving patients' quality of life by providing high-quality, patient-centric products and services. Resmed Inc's corporate philosophy centers around a commitment to innovation, excellence, and collaboration. By continuously investing in research and development, Resmed Inc aims to stay at the forefront of medical advancements and deliver effective and reliable solutions to the patients it serves.

Analysts currently set an average price target of 303.51 USD for the Resmed stock (median: 306.00 USD), implying +34.3 % versus the latest price. The consensus is based on 25 analyst ratings.

Resmed Analyst Price Targets 2026

25 analysts currently rate the Resmed stock: 16 recommend buying, 8 holding and 1 selling.

Resmed Analyst Price Targets 2026

Converted at the current exchange rate, the Resmed share trades at 190.29 EUR (219.47 USD).

The Resmed share (RMD) is listed on 10 stock exchanges, including: NYSE (RMD), Frankfurt (RME.F), München (RME.MU), Stuttgart (RME.SG), Düsseldorf (RME.DU), Berlin (RME.BE), London (0KW4.L), London (0KW4.L).

ResMed Inc. is a global company specialized in the development, manufacturing, and marketing of sleep apnea therapy products. Its business model is based on helping people around the world improve their sleep quality and promote their health. The company is divided into three main divisions: sleep and ventilation therapy, diagnostics, and software and services. The sleep and ventilation therapy division includes the production of ventilation devices, masks, and accessories that help keep the airway open during sleep and ensure optimal oxygen supply to the body. The diagnostics division offers solutions for detecting sleep disorders such as sleep apnea, including recording devices and software that can measure and analyze the patient's sleep behavior. The software and services division includes various solutions for medical professionals and patients to monitor and optimize therapy. ResMed Inc. is a pioneer in the industry and is considered an innovation leader in sleep apnea therapy. The company works closely with leading doctors and researchers to continuously develop new and improved products. ResMed Inc. also has a strong presence in the global market and operates in over 100 countries worldwide. One of ResMed Inc.'s most well-known products is the AirSense™ 10 AutoSet™, an intelligent ventilation device that automatically provides the patient with optimal respiratory support based on sensors and algorithms. The AirFit™ mask range from ResMed provides the patient with a comfortable and secure fit for successful therapy. ResMed Inc. also offers a variety of mobile apps that enable easy monitoring and management of the patient's therapy. ResMed Inc. also utilizes its industry-leading expertise to collaborate with other companies and organizations. For example, the company partners with medical device manufacturers and pharmaceutical companies to develop innovative solutions for the healthcare industry. ResMed Inc. has established itself as a trusted partner for medical professionals and patients. The company takes a holistic approach to sleep apnea therapy by engaging and educating patients and healthcare professionals. ResMed Inc. is always striving to improve the lives of patients with sleep apnea and provide them with a higher quality of life. Overall, ResMed Inc.'s business model is focused on the development and production of high-quality and innovative products for sleep apnea therapy. The company continually pursues new approaches to improve the quality of therapy for patients, always with the goal of promoting the health and well-being of its users.

The revenue of Resmed is 5.65 B USD. This figure is based on current financial data and reflects the company's business performance.

The profit of Resmed is 1.52 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Resmed is currently 20.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Resmed stock.

The price-to-sales ratio (P/S) of Resmed is currently 5.63. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Resmed stock.

The Eulerpool Quality Score for Resmed is 8/10.

The ISIN of Resmed is US7611521078. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Resmed is 895878. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Resmed is RMD. The ticker symbol is used to trade Resmed shares on the stock exchange.

Over the past 12 months, Resmed paid a dividend of 2.40 USD . This corresponds to a dividend yield of about 1.09 %. For the coming 12 months, Resmed is expected to pay a dividend of 2.62 USD.

The current dividend yield of Resmed is 1.09 %.

Resmed pays a dividend, distributed in the months of , , , .

Resmed paid dividends every year for the past 14 years.

For the upcoming 12 months, dividends amounting to 2.62 USD are expected. This corresponds to a dividend yield of 1.19 %.

Resmed is assigned to the 'Health' sector.

In the year 2025, Resmed distributed 1.92 USD as dividends.

The dividends of Resmed are distributed in USD.

All fundamentals and in-depth analysis of Resmed

Our stock analysis for Resmed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Resmed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Resmed Stock
Resmed Revenue→
Resmed Stock
Resmed Net Income→
Resmed Stock
Resmed P/E→
Resmed Stock
Resmed P/S→
Resmed Stock
Resmed EBIT→
Resmed Stock
Resmed Dividend→
Resmed Stock
Resmed Directors Dealings→
Resmed Stock
Resmed Stocks→
Resmed Stock
Resmed Market capitalization→
Resmed Stock
Resmed Debt→
Resmed Stock
Resmed Liabilities→
Resmed Stock
Resmed Equity→
Resmed Stock
Resmed AAQS→
Resmed Stock
Resmed Employees→
Resmed Stock
Resmed ROE→
Resmed Stock
Resmed ROA→
Resmed Stock
Resmed ROCE→
Resmed Stock
Resmed News→
Resmed Stock
Resmed Analyst Price Targets→

Health Stocks

Resonance HealthResapp HealthRespiratorius AB (publ)Republic HealthcareResponse GeneticsReproCellRestart Life SciencesReplimune GroupRetinalGenix TechnologiesRepligenRetractable TechnologiesRenovoRxAll Stocks A–Z →